Mechanism of Complement Activation and Its Role in the Inflammatory Response After Thoracoabdominal Aortic Aneurysm Repair
Background— Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation. Methods and Results— The degree and mechanism of complement activation and it...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 108; no. 7; pp. 849 - 856 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Heart Association, Inc
19.08.2003
|
Subjects | |
Online Access | Get full text |
ISSN | 0009-7322 1524-4539 1524-4539 |
DOI | 10.1161/01.CIR.0000084550.16565.01 |
Cover
Loading…
Abstract | Background—
Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation.
Methods and Results—
The degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1β, tumor necrosis factor α (TNF-α), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1β, TNF-α, or IL-8 in a mannose-binding lectin (MBL)–deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients.
Conclusions—
The data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response. |
---|---|
AbstractList | Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation.BACKGROUNDComplement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation.The degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1beta, tumor necrosis factor alpha (TNF-alpha), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1beta, TNF-alpha, or IL-8 in a mannose-binding lectin (MBL)-deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients.METHODS AND RESULTSThe degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1beta, tumor necrosis factor alpha (TNF-alpha), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1beta, TNF-alpha, or IL-8 in a mannose-binding lectin (MBL)-deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients.The data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response.CONCLUSIONSThe data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response. Background— Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation. Methods and Results— The degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1β, tumor necrosis factor α (TNF-α), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1β, TNF-α, or IL-8 in a mannose-binding lectin (MBL)–deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients. Conclusions— The data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response. Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation. The degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1beta, tumor necrosis factor alpha (TNF-alpha), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1beta, TNF-alpha, or IL-8 in a mannose-binding lectin (MBL)-deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients. The data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response. BACKGROUND: Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation. METHODS AND RESULTS: The degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1beta, tumor necrosis factor alpha (TNF-alpha), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1beta, TNF-alpha, or IL-8 in a mannose-binding lectin (MBL)-deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients. CONCLUSIONS: The data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response. |
Author | Heggelund, Lars Lingaas, Per S. Fiane, Arnt E. Fung, Michael Videm, Vibeke Geiran, Odd R. Mollnes, Tom E. Nielsen, Erik W. |
Author_xml | – sequence: 1 givenname: Arnt E. surname: Fiane fullname: Fiane, Arnt E. organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V – sequence: 2 givenname: Vibeke surname: Videm fullname: Videm, Vibeke organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V – sequence: 3 givenname: Per S. surname: Lingaas fullname: Lingaas, Per S. organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V – sequence: 4 givenname: Lars surname: Heggelund fullname: Heggelund, Lars organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V – sequence: 5 givenname: Erik W. surname: Nielsen fullname: Nielsen, Erik W. organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V – sequence: 6 givenname: Odd R. surname: Geiran fullname: Geiran, Odd R. organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V – sequence: 7 givenname: Michael surname: Fung fullname: Fung, Michael organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V – sequence: 8 givenname: Tom E. surname: Mollnes fullname: Mollnes, Tom E. organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/12900342$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkV1rHCEUhqWkNJu0f6FILno3Wz_GUXvVYenHQkphSa_FcRzWMOpUncD219d8lECu6o34-pxz0OcCnIUYLABXGG0x7vBHhLe7_WGL7pdoGatxxzq2RfgV2GBG2qZlVJ6BTb2XDaeEnIOLnG_rsaOcvQHnmEiEaEs24M8Pa446uOxhnOAu-mW23oYCe1PcnS4uBqjDCPclw0OcLXQBlqOF-zDN2ntdYjrBg81LDNnCfio2wZtjTNpEPYzRu6Bn2MdUnIF9sGs61UkHu2iX3oLXk56zffe0X4JfX7_c7L431z-_7Xf9dWOooKXhujXUjELKjgySEo06zjrRSmGkplTzGmsqcEflRJGoIG8RaydJiB3GgdFL8OGx75Li79XmorzLxs6zDjauWXHKOBGcV_DqBXgb11QfkBXBhFMsJKrQ-ydoHbwd1ZKc1-mk_n1pBT49AibFnJOdnhGk7v0phFX1p579qQd_Na_Fn18UG1ceLJSk3fw_Lf4CLf2gzg |
CODEN | CIRCAZ |
CitedBy_id | crossref_primary_10_1080_14017430802302316 crossref_primary_10_1172_JCI31311 crossref_primary_10_2478_v10011_012_0004_3 crossref_primary_10_2310_6670_2006_00061 crossref_primary_10_4049_jimmunol_177_12_8626 crossref_primary_10_1007_s00772_018_0432_6 crossref_primary_10_1007_s13126_010_0015_9 crossref_primary_10_1007_s12035_014_8941_0 crossref_primary_10_1002_art_22302 crossref_primary_10_1016_S1877_8607_09_60008_4 crossref_primary_10_1111_j_1600_6143_2009_02675_x crossref_primary_10_1016_j_molimm_2009_04_028 crossref_primary_10_1097_SLA_0b013e3181784cc5 crossref_primary_10_1002_art_22662 crossref_primary_10_1038_s41598_024_63412_1 crossref_primary_10_1111_j_1537_2995_2007_01585_x crossref_primary_10_1016_j_molimm_2008_02_011 crossref_primary_10_1111_j_1365_2249_2004_02489_x crossref_primary_10_1016_j_amjcard_2024_04_007 crossref_primary_10_1016_j_ejvs_2005_09_012 crossref_primary_10_1007_s00380_010_0056_6 crossref_primary_10_1002_14651858_CD012926_pub2 crossref_primary_10_1038_ki_2012_373 crossref_primary_10_1016_S0002_9440_10_63424_4 crossref_primary_10_1016_j_jim_2007_04_004 crossref_primary_10_1038_sj_bjp_0706286 crossref_primary_10_1097_SLA_0b013e3181a38f45 crossref_primary_10_1007_s00772_019_0510_4 crossref_primary_10_1111_j_1445_2197_2007_04098_x crossref_primary_10_3390_jcm11092501 crossref_primary_10_3389_fimmu_2022_852119 crossref_primary_10_1016_j_avsg_2016_03_031 crossref_primary_10_1007_s12035_014_8682_0 crossref_primary_10_1021_acs_analchem_4c04416 crossref_primary_10_3389_fimmu_2023_1290684 crossref_primary_10_1016_j_ejca_2005_10_027 crossref_primary_10_1016_j_jvs_2007_08_032 crossref_primary_10_1016_j_avsg_2022_12_075 crossref_primary_10_1016_j_molimm_2006_06_020 crossref_primary_10_1007_s00268_005_7877_y crossref_primary_10_1016_j_imbio_2012_07_019 crossref_primary_10_1186_1471_2334_12_144 crossref_primary_10_1590_0102_6720201600010015 crossref_primary_10_2337_diabetes_54_5_1523 crossref_primary_10_4049_jimmunol_175_1_541 crossref_primary_10_2337_diabetes_53_6_1570 crossref_primary_10_3390_ijms18112374 crossref_primary_10_1053_j_jvca_2012_09_013 crossref_primary_10_1016_j_cellimm_2014_04_006 crossref_primary_10_1097_01_mot_0000127627_94212_76 crossref_primary_10_1007_s00595_007_3575_8 crossref_primary_10_2147_JIR_S344489 crossref_primary_10_3390_cells10071810 crossref_primary_10_1038_aps_2017_212 crossref_primary_10_1007_s10047_011_0577_5 crossref_primary_10_1016_j_athoracsur_2005_11_059 crossref_primary_10_1016_j_molimm_2005_06_014 crossref_primary_10_1016_j_cardfail_2006_07_002 crossref_primary_10_1016_j_avsg_2013_08_005 crossref_primary_10_1007_s00005_009_0029_6 crossref_primary_10_1038_aps_2011_151 crossref_primary_10_1111_j_1365_2249_2006_03072_x crossref_primary_10_1093_eurheartj_ehi198 crossref_primary_10_1186_s12893_020_00851_3 crossref_primary_10_1016_j_molimm_2006_10_003 crossref_primary_10_1177_0267659108097882 crossref_primary_10_1161_JAHA_124_036539 crossref_primary_10_4049_jimmunol_174_10_6373 crossref_primary_10_4103_bc_bc_133_24 crossref_primary_10_1007_s11064_013_1214_x crossref_primary_10_1177_1479164109336051 |
Cites_doi | 10.1016/0167-5699(87)90167-8 10.1016/S0002-9440(10)65026-2 10.1161/circ.104.12.1413 10.1016/S0162-3109(00)80303-3 10.1084/jem.180.5.1619 10.1016/0022-1759(93)90240-8 10.1016/S0002-9440(10)63839-4 10.1126/science.2371562 10.3109/00365518509155248 10.1161/circ.91.2.393 10.2165/00063030-200115090-00004 10.1006/jsre.2002.6385 10.1111/j.1365-3083.1988.tb02354.x 10.1046/j.1472-8206.2001.00040.x 10.1097/00024382-199609010-00003 10.1002/bjs.1800840209 10.1111/j.1365-3083.1985.tb01871.x 10.1046/j.1365-3083.1996.d01-57.x 10.1016/S0162-3109(99)00029-6 10.1097/00003246-200009000-00013 10.1016/S0161-5890(99)00118-2 10.1046/j.1365-3083.1997.d01-168.x 10.1093/cvr/28.4.437 10.1016/S0003-4975(97)00958-2 10.1084/jem.183.5.2343 10.1053/ejvs.2000.1147 10.1016/S0741-5214(97)70154-X 10.1152/jappl.1999.86.3.938 10.1016/S0022-1759(01)00453-7 10.1517/13543784.9.5.975 |
ContentType | Journal Article |
Copyright | Copyright American Heart Association, Inc. Aug 19 2003 |
Copyright_xml | – notice: Copyright American Heart Association, Inc. Aug 19 2003 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ U9A 7X8 |
DOI | 10.1161/01.CIR.0000084550.16565.01 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Career and Technical Education (Alumni Edition) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | 856 |
ExternalDocumentID | 388112281 12900342 10_1161_01_CIR_0000084550_16565_01 |
Genre | Controlled Clinical Trial Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 01R 0R~ 0ZK 18M 1J1 29B 2FS 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAAV AAAXR AAFWJ AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AARTV AASOK AAUEB AAWTL AAXQO AAYOK AAYXX ABBUW ABDIG ABJNI ABOCM ABPMR ABPXF ABQRW ABXVJ ABZAD ACCJW ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACOAL ACRKK ACWDW ACWRI ACXNZ ACZKN ADBBV ADCYY ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFCHL AFDTB AFEXH AFFNX AFNMH AFUWQ AGINI AHMBA AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW ALKUP ALMA_UNASSIGNED_HOLDINGS AMJPA AMNEI ASPBG AVWKF AYCSE AZFZN BAWUL BOYCO BQLVK BS7 BYPQX C1A C45 CITATION CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EX3 F2K F2L F2M F2N F5P FCALG FEDTE FL- FW0 GX1 H0~ H13 HVGLF HZ~ H~9 IKREB IKYAY IN~ J5H JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI KQ8 L-C L7B M18 N4W N9A NEJ N~7 N~B N~M O9- OAG OAH OBH OCB OCUKA ODA ODMTH OGEVE OHH OHT OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P2P PQQKQ R58 RAH RLZ S4R S4S T8P TEORI TR2 UPT V2I VVN W2D W3M W8F WH7 WHG WOQ WOW X3V X3W X7M XXN XYM YFH YOC YSK YYM YYP YZZ ZFV ZGI ZXP ZY1 ZZMQN ~H1 ACIJW AWKKM CGR CUY CVF ECM EIF NPM OJAPA OLW PKN RHF K9. NAPCQ U9A 7X8 |
ID | FETCH-LOGICAL-c383t-7a4c3cd89962b932a067568498c9a33a762ba381639f308d8974054f922ebdb53 |
ISSN | 0009-7322 1524-4539 |
IngestDate | Sun Aug 24 04:04:26 EDT 2025 Fri Jul 25 07:00:23 EDT 2025 Wed Feb 19 01:34:03 EST 2025 Thu Apr 24 22:58:07 EDT 2025 Tue Jul 01 02:06:24 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c383t-7a4c3cd89962b932a067568498c9a33a762ba381639f308d8974054f922ebdb53 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 |
PMID | 12900342 |
PQID | 212731890 |
PQPubID | 24119 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_73572877 proquest_journals_212731890 pubmed_primary_12900342 crossref_primary_10_1161_01_CIR_0000084550_16565_01 crossref_citationtrail_10_1161_01_CIR_0000084550_16565_01 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2003-08-19 2003-Aug-19 20030819 |
PublicationDateYYYYMMDD | 2003-08-19 |
PublicationDate_xml | – month: 08 year: 2003 text: 2003-08-19 day: 19 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Baltimore |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAlternate | Circulation |
PublicationYear | 2003 |
Publisher | American Heart Association, Inc |
Publisher_xml | – name: American Heart Association, Inc |
References | e_1_3_3_17_2 e_1_3_3_19_2 e_1_3_3_18_2 e_1_3_3_13_2 e_1_3_3_12_2 (e_1_3_3_20_2) 2002; 100 e_1_3_3_15_2 e_1_3_3_14_2 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 (e_1_3_3_16_2) 1999; 4 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_25_2 e_1_3_3_2_2 e_1_3_3_1_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_3_2 e_1_3_3_21_2 |
References_xml | – ident: e_1_3_3_2_2 doi: 10.1016/0167-5699(87)90167-8 – ident: e_1_3_3_29_2 doi: 10.1016/S0002-9440(10)65026-2 – ident: e_1_3_3_30_2 doi: 10.1161/circ.104.12.1413 – ident: e_1_3_3_1_2 doi: 10.1016/S0162-3109(00)80303-3 – ident: e_1_3_3_3_2 doi: 10.1084/jem.180.5.1619 – ident: e_1_3_3_19_2 doi: 10.1016/0022-1759(93)90240-8 – ident: e_1_3_3_31_2 doi: 10.1016/S0002-9440(10)63839-4 – ident: e_1_3_3_6_2 doi: 10.1126/science.2371562 – ident: e_1_3_3_24_2 doi: 10.3109/00365518509155248 – ident: e_1_3_3_27_2 doi: 10.1161/circ.91.2.393 – ident: e_1_3_3_11_2 doi: 10.2165/00063030-200115090-00004 – ident: e_1_3_3_5_2 doi: 10.1006/jsre.2002.6385 – ident: e_1_3_3_21_2 doi: 10.1111/j.1365-3083.1988.tb02354.x – ident: e_1_3_3_10_2 doi: 10.1046/j.1472-8206.2001.00040.x – ident: e_1_3_3_15_2 doi: 10.1097/00024382-199609010-00003 – ident: e_1_3_3_12_2 doi: 10.1002/bjs.1800840209 – ident: e_1_3_3_22_2 doi: 10.1111/j.1365-3083.1985.tb01871.x – ident: e_1_3_3_23_2 doi: 10.1046/j.1365-3083.1996.d01-57.x – ident: e_1_3_3_28_2 doi: 10.1016/S0162-3109(99)00029-6 – ident: e_1_3_3_13_2 doi: 10.1097/00003246-200009000-00013 – ident: e_1_3_3_8_2 doi: 10.1016/S0161-5890(99)00118-2 – ident: e_1_3_3_18_2 doi: 10.1046/j.1365-3083.1997.d01-168.x – ident: e_1_3_3_7_2 doi: 10.1093/cvr/28.4.437 – ident: e_1_3_3_4_2 doi: 10.1016/S0003-4975(97)00958-2 – ident: e_1_3_3_25_2 doi: 10.1084/jem.183.5.2343 – ident: e_1_3_3_33_2 doi: 10.1053/ejvs.2000.1147 – ident: e_1_3_3_14_2 doi: 10.1016/S0741-5214(97)70154-X – ident: e_1_3_3_26_2 doi: 10.1152/jappl.1999.86.3.938 – volume: 100 start-page: 1869 year: 2002 ident: e_1_3_3_20_2 publication-title: Blood – ident: e_1_3_3_17_2 doi: 10.1016/S0022-1759(01)00453-7 – volume: 4 start-page: 751 year: 1999 ident: e_1_3_3_16_2 publication-title: Cardiol Clin North Am – ident: e_1_3_3_32_2 – ident: e_1_3_3_9_2 doi: 10.1517/13543784.9.5.975 |
SSID | ssj0006375 |
Score | 2.068412 |
Snippet | Background—
Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer... Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive... BACKGROUND: Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 849 |
SubjectTerms | Aged Aged, 80 and over Aortic Aneurysm, Abdominal - complications Aortic Aneurysm, Abdominal - surgery Aortic Aneurysm, Thoracic - complications Aortic Aneurysm, Thoracic - surgery Cell Adhesion Molecules - metabolism Chemokines - blood Complement Activation - physiology Cytokines - blood Female Humans Inflammation - blood Inflammation - etiology Inflammation - physiopathology Lactoferrin - metabolism Male Mannose-Binding Lectin - deficiency Mannose-Binding Lectin - metabolism Middle Aged Neutrophil Activation Peroxidase - metabolism Plasma Prospective Studies Reperfusion Injury - etiology Reperfusion Injury - physiopathology Vascular Surgical Procedures - adverse effects |
Title | Mechanism of Complement Activation and Its Role in the Inflammatory Response After Thoracoabdominal Aortic Aneurysm Repair |
URI | https://www.ncbi.nlm.nih.gov/pubmed/12900342 https://www.proquest.com/docview/212731890 https://www.proquest.com/docview/73572877 |
Volume | 108 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELZCkRAXBC2PtDx8QNw2bNb7PEahUQppQShBuVle29uuaHfRdnNo_wP_mfFjH4VUFC6ryBvHlufLjMf-ZgahtwEPpUgC3xmTVDi-kJmTJMJ1hKt4NoFQdkexLU7C-cr_uA7Wg8HPHmtpU6cjfr01ruR_pAptIFcVJfsPkm1_FBrgM8gXniBheN5JxsdSxe2qMhcNOVwazjhvipZ1dwOKRWg5jTA04ODC3K9XhiQrbbXw-gwwwUuWitKU-2JlZXK6Slh9GKkC-5VX_T3tNK-4LQK2rbZP76xhlltm7aSCWbYxEN9UkVpNuM1T-b1F2kJV6zbxZl9gZu2udS5PT-X5xpyIL1h18-SCqKNYqx-tsvV8xw9MMqOR3NLWaGg37kEx6unb2OQ7_dMOhGMd2zCaHn01KSpjFb49UrmGVJ7Wzvo1N_4nn-lstVjQ5eF6eQ_d98DrUHr-w9Gn1rCHROdtbqdoc9jCWO9vH-nmfucWJ0ZvZpaP0SPrheCJgdQTNJDFLtqbFACJiyv8DmtesL5w2UUPji39Yg9dt4DDZYY7wOEOcBgAhwFwWAEO5wUGwOE-4HADOKwBh38HHDaAww3gsAHcU7SaHS6nc8cW73A4iUntRMznhAtw50MvBSeBKdc0BHnFPGGEMDDCKVO31iTJiBvDFyPwHfws8TyZijQgz9BOURbyBcIBByvhCs5SkviMu8zjEQNlkhEmuAjDIUqaJabcZrZXBVbOqfZwwzF1xxTEQzvxUC0eaB8i0vb9YfK73KnXQSNJavXBJVW1EsBCJu4QvWnfgrJWN3CwZuXmkkYkiLw4iobouRF_N6aX6Gyc-3_te4Aedn-ml2inrjbyFWyM6_S1husvaT600Q |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanism+of+complement+activation+and+its+role+in+the+inflammatory+response+after+thoracoabdominal+aortic+aneurysm+repair&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Fiane%2C+Arnt+E&rft.au=Videm%2C+Vibeke&rft.au=Lingaas%2C+Per+S&rft.au=Heggelund%2C+Lars&rft.date=2003-08-19&rft.issn=1524-4539&rft.eissn=1524-4539&rft.volume=108&rft.issue=7&rft.spage=849&rft_id=info:doi/10.1161%2F01.CIR.0000084550.16565.01&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |